Post-amputation pain (PAP), which includes both residual limb and phantom limb pain, affects up to 85% of amputees and severely impairs quality of life, mobility, and psychological well-being while incurring substantial healthcare costs. Conventional treatments - pharmacotherapy and neuromodulation techniques such as spinal cord stimulation and peripheral nerve stimulation - often provide inadequate relief and are associated with adverse effects like opioid dependence and systemic toxicity. The Altius High-Frequency Nerve Block System is an innovative therapeutic approach that delivers high-frequency alternating current (HFAC) directly to peripheral nerves, inducing a reversible conduction block without paresthesia. Clinical validation through the pivotal QUEST study - a multicenter, double-blind, randomized, active-sham controlled trial - has shown significant reductions in pain intensity and decreased reliance on pain medications in patients with chronic PAP. This review examines the physiological mechanisms of HFAC nerve block, outlines the development and clinical application of the Altius system, and evaluates its safety profile and broader implications for pain management. The findings suggest that the Altius system addresses a critical gap in PAP treatment, offering sustained pain relief, reduced opioid dependency, and improved quality of life for amputees.